These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 15614527)
1. Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cohen KA; Liu TF; Cline JM; Wagner JD; Hall PD; Frankel AE Cancer Immunol Immunother; 2005 Aug; 54(8):799-806. PubMed ID: 15614527 [TBL] [Abstract][Full Text] [Related]
2. Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys. Cohen KA; Liu TF; Cline JM; Wagner JD; Hall PD; Frankel AE Leuk Lymphoma; 2004 Aug; 45(8):1647-56. PubMed ID: 15370220 [TBL] [Abstract][Full Text] [Related]
3. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Urieto JO; Liu T; Black JH; Cohen KA; Hall PD; Willingham MC; Pennell LK; Hogge DE; Kreitman RJ; Frankel AE Protein Expr Purif; 2004 Jan; 33(1):123-33. PubMed ID: 14680969 [TBL] [Abstract][Full Text] [Related]
4. Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys. Hotchkiss CE; Hall PD; Cline JM; Willingham MC; Kreitman RJ; Gardin J; Latimer A; Ramage J; Feely T; DeLatte S; Tagge EP; Frankel AE Toxicol Appl Pharmacol; 1999 Jul; 158(2):152-60. PubMed ID: 10406930 [TBL] [Abstract][Full Text] [Related]
5. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Frankel A; Liu JS; Rizzieri D; Hogge D Leuk Lymphoma; 2008 Mar; 49(3):543-53. PubMed ID: 18297533 [TBL] [Abstract][Full Text] [Related]
6. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147 [TBL] [Abstract][Full Text] [Related]
7. Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: Implications for diphtheria fusion protein therapy. Hall PD; Sinha D; Frankel AE Cancer Immunol Immunother; 2006 Aug; 55(8):928-32. PubMed ID: 16645883 [TBL] [Abstract][Full Text] [Related]
8. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512 [TBL] [Abstract][Full Text] [Related]
10. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. Hogge DE; Willman CL; Kreitman RJ; Berger M; Hall PD; Kopecky KJ; McLain C; Tagge EP; Eaves CJ; Frankel AE Blood; 1998 Jul; 92(2):589-95. PubMed ID: 9657759 [TBL] [Abstract][Full Text] [Related]
11. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. Hall PD; Willingham MC; Kreitman RJ; Frankel AE Leukemia; 1999 Apr; 13(4):629-33. PubMed ID: 10214872 [TBL] [Abstract][Full Text] [Related]
12. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Alexander RL; Ramage J; Kucera GL; Caligiuri MA; Frankel AE Leuk Res; 2001 Oct; 25(10):875-81. PubMed ID: 11532521 [TBL] [Abstract][Full Text] [Related]
13. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice. Hall PD; Kreitman RJ; Willingham MC; Frankel AE Toxicol Appl Pharmacol; 1998 May; 150(1):91-7. PubMed ID: 9630457 [TBL] [Abstract][Full Text] [Related]
14. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Hogge DE; Yalcintepe L; Wong SH; Gerhard B; Frankel AE Clin Cancer Res; 2006 Feb; 12(4):1284-91. PubMed ID: 16489085 [TBL] [Abstract][Full Text] [Related]
15. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. Hogge DE; Feuring-Buske M; Gerhard B; Frankel AE Leuk Res; 2004 Nov; 28(11):1221-6. PubMed ID: 15380349 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of the recombinant fusion protein DAB486IL-2 in animal models. Bacha P; Forte S; Kassam N; Thomas J; Akiyoshi D; Waters C; Nichols J; Rosenblum M Cancer Chemother Pharmacol; 1990; 26(6):409-14. PubMed ID: 2225311 [TBL] [Abstract][Full Text] [Related]
17. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells. Feuring-Buske M; Frankel A; Gerhard B; Hogge D Exp Hematol; 2000 Dec; 28(12):1390-400. PubMed ID: 11146161 [TBL] [Abstract][Full Text] [Related]
18. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. Perentesis JP; Gunther R; Waurzyniak B; Yanishevski Y; Myers DE; Ek O; Messinger Y; Shao Y; Chelstrom LM; Schneider E; Evans WE; Uckun FM Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2217-27. PubMed ID: 9815618 [TBL] [Abstract][Full Text] [Related]
19. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707 [TBL] [Abstract][Full Text] [Related]
20. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. LeMaistre CF; Saleh MN; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Nichols JC Blood; 1998 Jan; 91(2):399-405. PubMed ID: 9427692 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]